We use the model to simulate the metabolic profiles previously observed in Down syndrome and autism and compare the model results to clinical data
The change in bone age, for those with measurements after at least 1 year of treatment up to a maximum 17 years of treatment, exceeded the change in chronological age by a mean of 0.9 years (SD = 1.8) (+ 7.4 years [SD = 3.7] versus + 6.5 years [SD = 3.7], respectively)
Besides helping with appetite, studies suggest that tesofensine may affect energy use and fat burning in the body and reduce the risk of heart disease
However, some people may experience mild swelling, bruising, or redness at the injection site
Its available in 31 states
Risk of Obesity Among School Teachers and its Associated Health Problems